Zalcitabine (Compound)

Synonyms:zalcitabine, Dideoxycytidine, 7481-89-2, 2',3'-DIDEOXYCYTIDINE, ddCyd, HIVID, Cytidine, 2',3'-dideoxy-, ddC, 4-Amino-1-((2R,5S)-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidin-2(1H)-one, Zalcitibine, NSC 606170, Ro 24-2027/000, Ro-24-2027/000, NSC-606170, CHEMBL853, 6L3XT8CB3I, 4-amino-1-[(2R,5S)-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidin-2(1H)-one, DTXSID0023747, CHEBI:10101, NCGC00090705-08, Ro-242027000, Ro-24-2027000, 4-AMINO-1-[(2R,5S)-5-(HYDROXYMETHYL)OXOLAN-2-YL]-1,2-DIHYDROPYRIMIDIN-2-ONE, 2,3-dideoxycytidine, DTXCID703747, NSC606170, 4-amino-1-[(2R,5S)-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidin-2-one, SMR000058253, CCRIS 692, Hivid(TM), Hivid (TN), HSDB 7156, Interferon AD + ddC, ddC & GM-CSF, ddC & sCD4, PC-SOD & ddC, DDC (DDC), UNII-6L3XT8CB3I, BRN 0654956, Zalcitabine (JAN/USP/INN), DS-4152 & ddC, 1-(2,3-Dideoxy-beta-D-ribofuranosyl)cytosine, ddC & NP (from PHCA or HSA), SRI-7707, Zalcitabine [USAN:USP:INN:BAN], 2',3'-Dideoxycytidine;ddC;Dideoxycytidine, CAS-7481-89-2, Zalcitabine- Bio-X, MFCD00012188, KS-1130, ddC & IFN.alpha., .beta.-D-DDC, dideoxycytidine (DDC), ZALCITABINE [MI], 4-amino-1-[(2R,5S)-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one, Prestwick0_001037, Prestwick1_001037, Prestwick2_001037, Prestwick3_001037, ddC & Interferon.alpha., ZALCITABINE [INN], ZALCITABINE [JAN], 2', 3'-dideoxycytidine, ZALCITABINE [HSDB], ZALCITABINE [IARC], ZALCITABINE [USAN], bmse000712, UPCMLD-DP115, D 5782, ZALCITABINE [VANDF], SCHEMBL3598, TimTec1_004969, ZALCITABINE [MART.], Lopac0_000360, BSPBio_001253, ZALCITABINE [USP-RS], ZALCITABINE [WHO-DD], 3'-Azido-3'-deoxythymidine/2',3'-Dideoxycytidine, 5-25-14-00313 (Beilstein Handbook Reference), MLS000069636, MLS000759540, MLS001055363, MLS001424210, MLS006011951, SPBio_003104, BPBio1_001378, GTPL4828, UPCMLD-DP115:001, 2',3'-Dideoxycytidine & sCD4(soluble recombinant protein), Zalcitabine (dideoxycytidine,ddc), ZALCITABINE [ORANGE BOOK], HMS1548B19, HMS1571O15, HMS2051H18, HMS2090C12, HMS2098O15, HMS2236N08, HMS3261G21, HMS3715O15, Pharmakon1600-01502360, ZALCITABINE [USP IMPURITY], .beta.-D-2',3'-Dideoxycytidine, Zalcitabine, 2'3'-Dideoxycytidine, BCP13878, Tox21_113491, Tox21_201655, Tox21_303169, Tox21_500360, AC-824, BDBM50145605, Lecithinized superoxide dismutase & .beta.-D-2',3'-Dideoxycytidine, NSC759655, s1719, AKOS015854844, AKOS015894505, Tox21_113491_1, CCG-101050, CS-1110, DB00943, LP00360, NC00300, NSC-759655, SDCCGSBI-0050348.P002, SRI-7707-13, SRI-7707-14, SRI-7707_15, SRI-7707_17, NCGC00090705-01, NCGC00090705-02, NCGC00090705-03, NCGC00090705-05, NCGC00090705-06, NCGC00090705-07, NCGC00090705-09, NCGC00090705-10, NCGC00090705-11, NCGC00090705-13, NCGC00090705-15, NCGC00090705-24, NCGC00090705-25, NCGC00179242-01, NCGC00257202-01, NCGC00259204-01, NCGC00261045-01, BD164564, BP-58631, HY-17392, ddC;Dideoxycytidine;2',3'-Dideoxycytidine, 2',3'-Dideoxycytidine & Interferon.alpha., 2',3'-Dideoxycytidine, >=98% (HPLC), DB-019728, D3581, EU-0100360, SW197364-4, 2',3'-Dideoxycytidine, >=99.0% (HPLC), C07207, C76390, D00412, EN300-120633, Cytidine, 2',3'-dideoxy- & Interferon.alpha., A838234, SR-01000075822, SR-01000736919, ZALCITABINE (DIDEOXYCYTIDINE,DDC) [VANDF], J-700276, Q-201941, Q2344582, SR-01000075822-1, SR-01000736919-5, Cytidine, 2',3'-dideoxy- & Colony-stimulating factor, Ro-242027000/Ro-24-2027-000, Z1550648753, Zalcitabine, United States Pharmacopeia (USP) Reference Standard, 4-Amino-1-(5-hydroxymethyl-tetrahydro-furan-2-yl)-1H-pyrimidin-2-one, .beta.-D-2',3'-Dideoxycytidine & Granulocyte-macrophage colony-stimulating factor

Id:24066

Description:nan